Confronta i metodi
Esamina i metodi selezionati fianco a fianco; le righe che differiscono sono evidenziate.
| Trial Clinico Bayesiano di Fase I× | Sperimentazione Clinica Adattiva di Fase I× | |
|---|---|---|
| Campo | Epidemiologia | Epidemiologia |
| Famiglia | Process / pipeline | Process / pipeline |
| Anno di origine≠ | 1990 | 1990 (model-based adaptive era); rule-based designs from the 1970s–1980s |
| Ideatore≠ | O'Quigley, Pepe & Fisher (Continual Reassessment Method) | O'Quigley, Pepe, and Fisher (CRM); earlier rule-based 3+3 designs pre-date it |
| Tipo≠ | Adaptive Bayesian dose-finding design | Adaptive clinical trial design |
| Fonte seminale | O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗ | O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗ |
| Alias≠ | Bayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study | adaptive dose-escalation trial, adaptive dose-finding study, model-based adaptive Phase I design |
| Correlati≠ | 5 | 1 |
| Sintesi≠ | A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses. | An adaptive Phase I clinical trial is a first-in-human or early-phase dose-finding study that continuously updates the recommended dose after each patient cohort using a prespecified statistical model, rather than following a fixed rule. The goal is to identify the maximum tolerated dose (MTD) or the recommended Phase II dose (RP2D) efficiently while minimising exposure of participants to sub-therapeutic or toxic doses. Adaptive designs — most notably the Continual Reassessment Method (CRM) — replace or augment traditional rule-based designs such as the 3+3 schema. |
| ScholarGateInsieme di dati ↗ |
|
|